Systemic Scleroderma Treatment Market

May 2021| MRS222A| Market Research Studies

Report Highlights

The scope of this report covers the different types of systemic scleroderma along with emerging drug classes for the treatment of systemic scleroderma. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each drug class, indication, distribution channel, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional systemic scleroderma treatment markets; it explains the major market drivers of the global systemic scleroderma treatment industry, current trends within the industry, major applications, and the regional dynamics of the global systemic scleroderma treatment market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global systemic scleroderma treatment market. Recent mergers and acquisitions, new product development is also catered in this report.

Report Includes

  • 36 tables and 44 figures
  • An up-to-date analysis of the Global Systemic Scleroderma Treatment Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for Global Systemic Scleroderma Treatment Market, and corresponding market share analysis by drug class, indication, distribution channel, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for systemic scleroderma treatment, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Systemic Scleroderma Treatment Market as compared to overall global economy.
  • Insight into the growth development strategies of major systemic scleroderma treatment manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, F. Hoffmann-La Roche AG, Eli Lilly and Company, Pfizer Inc., Boehringer Ingelheim International GmbH, arGentis Pharmaceuticals, LLC, Chemomab Ltd., and others.

Summary

Systemic scleroderma is an autoimmune rheumatic disorder that causes chronic hardening affecting the skin. This condition usually happens when the immune system of the body does not perform functionally and starts attacking the organ and tissues of its own body. In this condition, the tissues of the body are thickened and can even cause loss of pulmonary functions. The characteristic of systemic scleroderma is the changing of the appearance of the skin which is normally due to the escalated collagen production.

Apart from this, the systemic scleroderma can also affect the functioning of kidneys, digestive system, heart, blood vessels, and many other organs. The global systemic scleroderma treatment market growth is driven by various factors such as increasing screening rates of scleroderma, rising prevalence of the disease, and growing R&D activities for the treatment of systemic scleroderma.


Some of the symptoms of this disease includes, diarrhoea, esophageal reflux, joint pain, hair loss, shortness of breath, and others. There are mainly three types of systemic scleroderma namely limited, diffuse, and sine. It has been reported that approximately 75,000-80,000 of population suffer from systemic sclerosis.

The Global Systemic Scleroderma Treatment Market was valued at $1.38 billion in 2020 and is expected to witness a steady growth at a CAGR of 5.02%.

  • Table 1 : Global Systemic Scleroderma Treatment Market, Through 2026
  • Table 2 : Global Systemic Scleroderma Treatment, by Drug Class, Through 2026
  • Table 3 : Global Systemic Scleroderma Treatment, by Indication, Through 2026
  • Table 4 : Global Systemic Scleroderma Treatment, by Distribution Channel, Through 2026
  • Table 5 : Global Systemic Scleroderma Treatment, by Region, Through 2026
  • Table 6 : North America Systemic Scleroderma Treatment, by Drug Class, Through 2026
  • Table 7 : North America Systemic Scleroderma Treatment, by Indication, Through 2026
  • Table 8 : North America Systemic Scleroderma Treatment, by Distribution Channel, Through 2026
  • Table 9 : North America Systemic Scleroderma Treatment, by Country, Through 2026
  • Table 10 : Europe Systemic Scleroderma Treatment, by Drug Class, Through 2026
  • Table 11 : Europe Systemic Scleroderma Treatment, by Indication, Through 2026
  • Table 12 : Europe Systemic Scleroderma Treatment, by Distribution Channel, Through 2026
  • Table 13 : Europe Systemic Scleroderma Treatment, by Country, Through 2026
  • Table 14 : Asia-Pacific Systemic Scleroderma Treatment, by Drug Class, Through 2026
  • Table 15 : Asia-Pacific Systemic Scleroderma Treatment, by Indication, Through 2026
  • Table 16 : Asia-Pacific Systemic Scleroderma Treatment, by Distribution Channel, Through 2026
  • Table 17 : Asia-Pacific Systemic Scleroderma Treatment, by Country, Through 2026
  • Table 18 : South America Systemic Scleroderma Treatment, by Drug Class, Through 2026
  • Table 19 : South America Systemic Scleroderma Treatment, by Indication, Through 2026
  • Table 20 : South America Systemic Scleroderma Treatment, by Distribution Channel, Through 2026
  • Table 21 : South America Systemic Scleroderma Treatment, by Country, Through 2026
  • Table 22 : Middle East & Africa Systemic Scleroderma Treatment, by Drug Class, Through 2026
  • Table 23 : Middle East & Africa Systemic Scleroderma Treatment, by Indication, Through 2026
  • Table 24 : Middle East & Africa Systemic Scleroderma Treatment, by Distribution Channel, Through 2026
  • Table 25 : Middle East & Africa Systemic Scleroderma Treatment, by Country, Through 2026
  • Table 26 : F. Hoffmann-La Roche AG: Financial Performance, Through 2020
  • Table 27 : Eli Lilly and Company: Financial Performance, Through 2020
  • Table 28 : Pfizer Inc.: Financial Performance, Through 2020
  • Table 29 : Boehringer Ingelheim International GmbH: Financial Performance, Through 2020
  • Table 30 : arGentis Pharmaceuticals, LLC: Financial Performance, Through 2020
  • Table 31 : Chemomab Ltd.: Financial Performance, Through 2020
  • Table 32 : Corbus Pharmaceuticals Holdings Inc.: Financial Performance, Through 2020
  • Table 33 : Cumberland Pharmaceuticals, Inc.: Financial Performance, Through 2020
  • Table 34 : Novartis International AG: Financial Performance, Through 2020
  • Table 35 : Bayer AG: Financial Performance, Through 2020
  • Table 36 : GlaxoSmithKline plc: Financial Performance, Through 2020
  • Figure 1 : Global Systemic Scleroderma Treatment Market
  • Figure 2 : Global Systemic Scleroderma Treatment, by Value, 2019-2026
  • Figure 3 : Global Systemic Scleroderma Treatment, by Value, by Drug Class, 2019-2026
  • Figure 4 : Global Systemic Scleroderma Treatment, by Value, by Indication, 2019-2026
  • Figure 5 : Global Systemic Scleroderma Treatment, by Value, by Distribution Channel, 2019-2026
  • Figure 6 : Global Systemic Scleroderma Treatment, by Value, by Region, 2020
  • Figure 7 : Global Systemic Scleroderma Treatment, by Value, by Company, 2020
  • Figure 8 : Global Systemic Scleroderma Treatment, Product Map, 2020
  • Figure 9 : North America Systemic Scleroderma Treatment, by Value, 2019-2026
  • Figure 10 : North America Systemic Scleroderma Treatment, by Value, by Drug Class, 2019-2026
  • Figure 11 : North America Systemic Scleroderma Treatment, by Value, by Indication, 2019-2026
  • Figure 12 : North America Systemic Scleroderma Treatment, by Value, by Distribution Channel, 2019-2026
  • Figure 13 : North America Systemic Scleroderma Treatment, by Value, by Country, 2020
  • Figure 14 : Europe Systemic Scleroderma Treatment, by Value, 2019-2026
  • Figure 15 : Europe Systemic Scleroderma Treatment, by Value, by Drug Class, 2019-2026
  • Figure 16 : Europe Systemic Scleroderma Treatment, by Value, by Indication, 2019-2026
  • Figure 17 : Europe Systemic Scleroderma Treatment, by Value, by Distribution Channel, 2019-2026
  • Figure 18 : Europe Systemic Scleroderma Treatment, by Value, by Country, 2020
  • Figure 19 : Asia-Pacific Systemic Scleroderma Treatment, by Value, 2019-2026
  • Figure 20 : Asia-Pacific Systemic Scleroderma Treatment, by Value, by Drug Class, 2019-2026
  • Figure 21 : Asia-Pacific Systemic Scleroderma Treatment, by Value, by Indication, 2019-2026
  • Figure 22 : Asia-Pacific Systemic Scleroderma Treatment, by Value, by Distribution Channel, 2019-2026
  • Figure 23 : Asia-Pacific Systemic Scleroderma Treatment, by Value, by Country, 2020
  • Figure 24 : South America Systemic Scleroderma Treatment, by Value, 2019-2026
  • Figure 25 : South America Systemic Scleroderma Treatment, by Value, by Drug Class, 2019-2026
  • Figure 26 : South America Systemic Scleroderma Treatment, by Value, by Indication, 2019-2026
  • Figure 27 : South America Systemic Scleroderma Treatment, by Value, by Distribution Channel, 2019-2026
  • Figure 28 : South America Systemic Scleroderma Treatment, by Value, by Country, 2020
  • Figure 29 : Middle East & Africa Systemic Scleroderma Treatment, by Value, 2019-2026
  • Figure 30 : Middle East & Africa Systemic Scleroderma Treatment, by Value, by Drug Class, 2019-2026
  • Figure 31 : Middle East & Africa Systemic Scleroderma Treatment, by Value, by Indication, 2019-2026
  • Figure 32 : Middle East & Africa Systemic Scleroderma Treatment, by Value, by Distribution Channel, 2019-2026
  • Figure 33 : Middle East & Africa Systemic Scleroderma Treatment, by Value, by Country, 2020
  • Figure 34 : F. Hoffmann-La Roche AG: Revenue Share, 2020
  • Figure 35 : Eli Lilly and Company: Revenue Share, 2020
  • Figure 36 : Pfizer Inc.: Revenue Share, 2020
  • Figure 37 : Boehringer Ingelheim International GmbH: Revenue Share, 2020
  • Figure 38 : arGentis Pharmaceuticals, LLC: Revenue Share, 2020
  • Figure 39 : Chemomab Ltd.: Revenue Share, 2020
  • Figure 40 : Corbus Pharmaceuticals Holdings Inc.: Revenue Share, 2020
  • Figure 41 : Cumberland Pharmaceuticals, Inc.: Revenue Share, 2020
  • Figure 42 : Novartis International AG: Revenue Share, 2020
  • Figure 43 : Bayer AG: Revenue Share, 2020
  • Figure 44 : GlaxoSmithKline plc: Revenue Share, 2020

Market Research Studies is a North Carolina based, premier market research company. MRS brings over 50 years of market research publishing experience. Our reports cover a variety of industries such as Healthcare, Chemicals, Materials & Manufacturing, Research & Diagnostics, Environment & Sustainability, among others. Each year MRS releases hundreds of reports covering various topics. These reports are prepared by our in-house of team of Industry expert analysts. We strive to provide in-depth market analysis with accurate data to help our customers make informed decisions.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report